Welcome to our first issue of the HendlerLaw Electronic Newsletter.

Our intent is to provide you, our clients, friends and colleagues, with helpful and important information. Periodically we will send you this e-mail with news briefs and articles about promising treatments for serious toxic injuries, new strategies for coping with related illnesses and updates on legal matters affecting our areas of practice.

We sincerely hope that you find this information of value and welcome your comments and suggestions. We also welcome you to visit any of our resource websites for the latest additional in-depth information and news.

On behalf of everyone at HendlerLaw, I'd like to take this opportunity to reiterate our commitment to providing our clients and their loved ones with high quality services that help them cope with the many challenges they face as a result of their injuries.

Comments or Suggestions?

Sincerely,
Scott Hendler

Visit www.hendlerlaw.com or any of our firm sponsored resource websites:

www.mesotheliomaadvice.com
www.silicosisadvice.com
www.ppaadvice.com
www.vioxxadvice.com
www.oxycontinadvice.com


Mesthelioma

New treatment offers hope for mesothelioma patients.
Article

Recent study highlights the broad scope of the asbestos-disease epidemic in America.
Article

Asbestos Disease Awareness Organization (ADAO) seeks to serve as the united voice for all asbestos victims.
Visit site

Experimental Surgery Gives Cancer Patient Hope.
Article

Silicosis

Courts debate whether sandblasting companies or the manufacturers who sell them sand will be held financially responsible for compensating workers who develop silicosis.
Article

OxyContin

New Drug Helps Addicts Detox.
Article

Drugmaker Purdue Pharma was still questioned in Judge James Jones' opinion.
Article

New guidelines issued to help provide better pain treatment.
Article

PPA

Chattem Announces Court States Intention to Approve Final PPA Settlement.
Article

Lawsuit claims former Dexatrim ingredient may be connected to Cape Coral woman's stroke.
Article

Vioxx

Vioxx Faces Challenges from Insurers, Lawyers.
Article

Vioxx study suggests heart risks; Kaiser to review.
Article
 
 

  Back to Top Legal Disclaimer | Privacy Policy